BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11762642)

  • 1. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
    Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
    Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
    Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
    Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC
    Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y; Takebayashi Y; Pommier Y
    Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Kasprzyk PG; Bailly C; Camara J; Bigg DC
    Anticancer Drugs; 2001 Jan; 12(1):9-19. PubMed ID: 11272292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
    Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
    Lavergne O; Lesueur-Ginot L; Pla Rodas F; Kasprzyk PG; Pommier J; Demarquay D; Prévost G; Ulibarri G; Rolland A; Schiano-Liberatore AM; Harnett J; Pons D; Camara J; Bigg DC
    J Med Chem; 1998 Dec; 41(27):5410-9. PubMed ID: 9876111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
    Lavergne O; Demarquay D; Bailly C; Lanco C; Rolland A; Huchet M; Coulomb H; Muller N; Baroggi N; Camara J; Le Breton C; Manginot E; Cazaux JB; Bigg DC
    J Med Chem; 2000 Jun; 43(11):2285-9. PubMed ID: 10841808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
    Larsen AK; Gilbert C; Chyzak G; Plisov SY; Naguibneva I; Lavergne O; Lesueur-Ginot L; Bigg DC
    Cancer Res; 2001 Apr; 61(7):2961-7. PubMed ID: 11306474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
    Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
    Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.
    Zhu L; Cheng P; Lei N; Yao J; Sheng C; Zhuang C; Guo W; Liu W; Zhang Y; Dong G; Wang S; Miao Z; Zhang W
    Arch Pharm (Weinheim); 2011 Nov; 344(11):726-34. PubMed ID: 21956522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells.
    Chauvier D; Morjani H; Manfait M
    Int J Oncol; 2002 Apr; 20(4):855-63. PubMed ID: 11894136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.